Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spermosens ABXSAT:SPERM +4.08% 5-Year ROIIC % is -42.83 as of Dec. 2025. Among 189 Medical Diagnostics & Research companies, Spermosens AB ranks worse than 77.78% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Spermosens AB's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was -42.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Spermosens AB's 5-Year ROIIC % or its related term are showing as below:
XSAT:SPERM's 5-Year ROIIC % is ranked worse than 77.78% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.74
vs XSAT:SPERM: -42.83
Spermosens AB (XSAT:SPERM) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Spermosens AB 5-Year ROIIC % Related Terms
Spermosens AB 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Spermosens AB's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:SPERM vs TMO, DHR, IDXX: 5-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Spermosens AB's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spermosens AB 5-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Spermosens AB's 5-Year ROIIC % falls into.
Spermosens AB's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -9.201 (Dec. 2025) - -2.041 (Dec. 2020) )
/
( 27.543 (Dec. 2025) - 10.826 (Dec. 2020) )
=
-7.16
/
16.717
=
-42.83%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Spermosens AB (XSAT:SPERM) has a 5-Year ROIIC % of -42.83 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Spermosens AB and its competitors. According to the industry distribution chart, Spermosens AB ranks #147 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 77.8%.
Is Spermosens AB's 5-Year ROIIC % too high?
Spermosens AB's current 5-Year ROIIC % is -42.83. Based on the distribution chart, Spermosens AB ranks #147 out of 189 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Spermosens AB's 5-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spermosens AB ranks #147 out of 189 companies for 5-Year ROIIC %. This places Spermosens AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Diagnostics & Research company?
A good 5-Year ROIIC % depends on the Medical Diagnostics & Research industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Spermosens AB and its competitors. Spermosens AB's current 5-Year ROIIC % is -42.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spermosens AB stock overvalued right now?
Spermosens AB (XSAT:SPERM) has a current 5-Year ROIIC % of -42.83. The current 5-Year ROIIC % is -42.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Spermosens AB (XSAT:SPERM), the current 5-Year ROIIC % is -42.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:SPERM has been successfully added to your 
